Monoclonal antibody · Antagonist of interleukin-18 (IL18) · developed by Avalo Therapeutics
Camoteskimab is a human IgG1 monoclonal antibody that binds interleukin-18 (IL-18), a member of the IL-1 cytokine superfamily, and inhibits IL-18-mediated signaling and inflammation. It is being studied in multiple myeloma, where elevated IL-18 is associated with disease progression.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04671251 | Phase 1 | Multiple Myeloma | Completed | AVTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Myeloma
Updated Oct 11, 2026. Something wrong or missing? Report it on the AVTX page.
See AVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AVTX catalysts and pipeline →